These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 20238314)

  • 21. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R; Elkins M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD007923. PubMed ID: 30480755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].
    Derelle J; Bertolo-Houriez E; Marchal F; Weber M; Virion JM; Vidailhet M
    Arch Pediatr; 1998 Apr; 5(4):371-7. PubMed ID: 9759155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of dornase alfa in the treatment of cystic fibrosis.
    Cramer GW; Bosso JA
    Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nebulised hypertonic saline for cystic fibrosis.
    Wark PA; McDonald V
    Cochrane Database Syst Rev; 2003; (1):CD001506. PubMed ID: 12535409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.
    Goa KL; Lamb H
    Pharmacoeconomics; 1997 Sep; 12(3):409-22. PubMed ID: 10170464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nebulised hypertonic saline for cystic fibrosis.
    Wark PA; McDonald V; Jones AP
    Cochrane Database Syst Rev; 2005 Jul; (3):CD001506. PubMed ID: 16034863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.
    Bryson HM; Sorkin EM
    Drugs; 1994 Dec; 48(6):894-906. PubMed ID: 7533697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
    Nash EF; Stephenson A; Ratjen F; Tullis E
    Cochrane Database Syst Rev; 2009 Jan; (1):CD007168. PubMed ID: 19160327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dornase alfa: a new option in the management of cystic fibrosis.
    Witt DM; Anderson L
    Pharmacotherapy; 1996; 16(1):40-8. PubMed ID: 8700791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis.
    McKenzie SG; Chowdhury S; Strandvik B; Hodson ME;
    Pediatr Pulmonol; 2007 Oct; 42(10):928-37. PubMed ID: 17726701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.
    Johnson CA; Butler SM; Konstan MW; Breen TJ; Morgan WJ
    J Pediatr; 1999 Jun; 134(6):734-9. PubMed ID: 10356143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.
    Tam J; Nash EF; Ratjen F; Tullis E; Stephenson A
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD007168. PubMed ID: 23852992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nebuliser systems for drug delivery in cystic fibrosis.
    Stanford G; Morrison L; Brown C
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007639. PubMed ID: 37942828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nebulised hypertonic saline for cystic fibrosis.
    Wark P; McDonald VM
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001506. PubMed ID: 19370568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period.
    Shah PL; Conway S; Scott SF; Rainisio M; Wildman M; Stableforth D; Hodson ME
    Respiration; 2001; 68(2):160-4. PubMed ID: 11287830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.
    Lands LC; Stanojevic S
    Cochrane Database Syst Rev; 2016 Apr; 4():CD001505. PubMed ID: 27055154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
    Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
    Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.
    Suri R; Metcalfe C; Lees B; Grieve R; Flather M; Normand C; Thompson S; Bush A; Wallis C
    Lancet; 2001 Oct; 358(9290):1316-21. PubMed ID: 11684212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.